Home › Non-Hodgkin Lymphoma › Nebraska › Omaha
Non-Hodgkin Lymphoma clinical trials in Omaha, NE
14 studies for Non-Hodgkin Lymphoma are looking for participants at sites in and around Omaha (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- University of Nebraska Medical Center, Omaha
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
- The University of Nebraska Medical Center, Omaha
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
RecruitingPhase 1/2
- Local Institution - 0124, Omaha
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RecruitingPhase 2
- Nebraska Cancer Specialists, Omaha
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- University of Nebraska Medical Center, Omaha
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RecruitingPhase 1
- University of Nebraska Medical Center, Omaha
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- University of Nebraska Medical Center (UNMC), Omaha
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- University of Nebraska Medical Center, Omaha
Halt Aging in Survivors of Blood Cancers
Recruiting
- University of Nebraska Medical Center, Omaha
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RecruitingPhase 1/2
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingPhase 1/2
- Fred and Pamela Buffett Cancer Center, Omaha
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RecruitingPhase 4
- University Of Nebraska Medical Center, Omaha
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RecruitingPhase 4
- University Of Nebraska Medical Center, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Omaha
Non-Hodgkin Lymphoma trials in other cities
- Houston, TX31 studies
- New York City, NY31 studies
- Boston, MA26 studies
- Nashville, TN21 studies
- Philadelphia, PA20 studies
- Baldwin Park, CA19 studies
- Atlanta, GA18 studies
- Columbus, OH18 studies
- Chicago, IL18 studies
- Milwaukee, WI18 studies
- Washington, DC18 studies
- Dallas, TX17 studies
Other studies in Omaha
- Prostate Cancer27 studies
- Non-Small Cell Lung Cancer24 studies
- Breast Cancer22 studies
- Colorectal Cancer18 studies
- Cancer (all types)18 studies
- Multiple Myeloma16 studies
- Ovarian Cancer14 studies
- Pancreatic Cancer14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Heart Failure13 studies
- Metastatic Cancer13 studies
- Kidney Cancer (Renal Cell Carcinoma)12 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.